GTBP GT Biopharma, Inc.


$ 0.67 $ 0.00 (0 %)    

Wednesday, 19-Nov-2025 08:10:52 EST
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
$ 0.67
$ 0.66 x 3
$ 0.69 x 200
-- - --
$ 0.54 - $ 4.10
774,928
na
6.97M
$ 1.24
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 gt-biopharma-advances-potent-nk-cell-therapies-as-gtb-3650-is-currently-being-tested-in-phase-1-trials-for-patients-with-relapsed-or-refractory-acute-myeloid-leukemia

 Within this landscape, GT Biopharma (NASDAQ:GTBP) is advancing a proprietary platform designed to harness NK cells against can...

 gt-biopharma-q2-eps-055-beats-068-estimate

GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.68) ...

 gt-biopharma-initiated-dosing-in-cohort-3-of-its-phase-1-dose-escalation-trial-of-gtb-3650-for-relapsed-or-refractory-cd33-expressing-hematologic-malignancies-plans-on-releasing-initial-phase-1-results-later-in-2025-following-completion-of-additional-dose-cohorts

The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION